Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Taysha Gene Therapies Inc (TSHA)

Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Taysha Gene Therapies Inc 3000 Pegasus Park Dr. Ste 1430 DALLAS TX 75247 USA

www.tayshagtx.com Employees: 73 P: 214-612-0000

Sector:

Medical

Description:

Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.

Key Statistics

Overview:

Market Capitalization, $K 1,506,555
Enterprise Value, $K 1,411,005
Shares Outstanding, K 273,919
Annual Sales, $ 8,330 K
Annual Net Income, $ -89,300 K
Last Quarter Sales, $ 1,990 K
Last Quarter Net Income, $ -26,880 K
EBIT, $ -89,160 K
EBITDA, $ -87,910 K
60-Month Beta 1.06
% of Insider Shareholders 3.78%
% of Institutional Shareholders 77.70%
Float, K 263,565
% Float 96.22%
Short Interest 48,587
Short Float 17.74%
Short Volume Ratio 0.64

Growth:

1-Year Return 183.78%
3-Year Return 173.63%
5-Year Return -79.78%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.09 on 11/04/25
Next Earnings Date 02/25/26
Earnings Per Share ttm -0.33
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 0.00%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

TSHA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -67.26%
Return-on-Assets % -42.14%
Profit Margin % -1,072.03%
Debt/Equity 0.17
Price/Sales 186.05
Price/Cash Flow N/A
Price/Book 7.05
Book Value/Share 0.91
Interest Coverage -892.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar